 This study will explore the safety and efficacy of the oral PanHER inhibitor PF-00299804 in patients with adenocarcinoma of the lung who are either non-smokers 100 cigarette, cigar or pipe lifetime or former light smokers less than 10 pack-years and stopped at least 15 years or have known EGFR activating mutation; or patients with HER 2 amplification or mutation. 